Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Invivo Therapeutics Holdings Corp (NVIV)

Invivo Therapeutics Holdings Corp (NVIV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment Conference

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard...

NVIV : 7.98 (+83.03%)
InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced the appointment...

NVIV : 7.98 (+83.03%)
InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the publication of a peer-reviewed manuscript in Neurosurgery describing the previously disclosed 12- and 24-month data from the Company's...

NVIV : 7.98 (+83.03%)
InVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has...

NVIV : 7.98 (+83.03%)
InVivo Therapeutics Announces Reverse Stock Split

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized common stock. The company anticipates...

NVIV : 7.98 (+83.03%)
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect Conference

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard...

NVIV : 7.98 (+83.03%)
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard...

NVIV : 7.98 (+83.03%)
InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has...

NVIV : 7.98 (+83.03%)
BioFlyte Forms Scientific Advisory Board of Prominent Government and Life Science Experts

BioFlyte , a biodetection company with a revolutionary new class of fieldable biological threat collection, detection, and identification solutions, today announced the formation of a Scientific Advisory...

NVIV : 7.98 (+83.03%)
PKI : 129.61 (-1.32%)
CBM : 59.99 (unch)
InVivo Therapeutics Announces FDA Acceptance of Preclinical Module in Support of Company’s Complete HDE Submission

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced the acceptance...

NVIV : 7.98 (+83.03%)

Barchart Exclusives

Pre-Market Brief: Stocks Mixed as Key U.S. Payrolls Data Looms
December S&P 500 futures (ESZ22) are trending down -0.12% this morning after three major US benchmark indices extended declines for the second successive trading session as investors digested remarks from several Federal Reserve officials about the path of future interest rate hikes ahead of the crucial monthly U.S. jobs report. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar